



CORRECTION

Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Alessio Aghemo · Yves Horsmans · Stefan Bourgeois · Mark Bondin · Michael Gschwantler · Harald Hofer · Nasser Semmo · Francesco Negro · Zhenzhen Zhang · John Marcinak · Ella Veitsman · Rawi Hazzan · Konstantinos Mimidis · Ioannis Goulis · Nuno Marques · Robert Flisiak · Wlodzimierz Mazur · Carlos Roncero · Fiona Marra · Georges Philippe Pageaux · Tarik Asselah · Pietro Lampertico

© The Author(s) 2021

Correction to: Infect Dis Ther

<https://doi.org/10.1007/s40121-021-00455-1>

In the Original publication of the article the key summary points were incorrectly published. This has been corrected here.

Key Summary Points

Why carry out this study

The global elimination of HCV infection is a possibility with the availability of short-course pangenotypic direct-acting antivirals, however rapid expansion of treatment to historically marginalized patients is necessary to achieve the goal of elimination.

The original article can be found online at <https://doi.org/10.1007/s40121-021-00455-1>.

A. Aghemo
Department of Biomedical Sciences, Humanitas University, Rozzano, Italy

Y. Horsmans
Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium

S. Bourgeois
Stuivenberg ZNA, Antwerp, Belgium

M. Bondin · Z. Zhang · J. Marcinak
AbbVie Inc, North Chicago, IL, USA

M. Gschwantler
Department of Internal Medicine IV, Wilhelminenspital, and Sigmund Freud University, Vienna, Austria

H. Hofer
Department of Internal Medicine, Gastroenterology and Hepatology, Klinikum Wels-Grieskirchen, Wels, Austria

N. Semmo
Department of BioMedical Research, Hepatology, Inselspital, University of Bern, 3010 Bern, Switzerland

F. Negro
Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland

E. Veitsman
Liver Unit, Rambam Health Care Campus, Haifa, Israel

This multinational study presents the efficacy, safety, and patient-reported outcomes of treatment with G/P in historically underserved patient populations in real-world settings.

What was learned from the study?

Overall, G/P treatment was highly effective with a cure rate of 98% and well-tolerated across a broad range of marginalized patients with chronic HCV and single or dual comorbidities.

Results from this real-world analysis address current gaps in clinical knowledge regarding impact on quality of life and G/P treatment led to improvements in health-related quality of life and reductions in fatigue.

These results further support the use of an 8-week short-course G/P in underserved patients including those with substance abuse and psychiatric comorbidities.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

R. Hazzan
Emek Medical Center, Afula, Israel

K. Mimidis
First Department of Internal Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece

I. Goulis
4th Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

N. Marques
Infectious Diseases Service, Hospital Garcia de Orta EPE, Almada, Portugal

R. Flisiak
Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland

W. Mazur
Clinical Department of Infectious Diseases, Medical University of Silesia, Katowice, Poland

C. Roncero
Psychiatry Service, University of Salamanca Health Care Complex, Salamanca, Spain

F. Marra
Hepatology Drug Interactions Group, University of Liverpool, Liverpool, UK

G. P. Pageaux
Département Hépatogastro-Entérologie, Centre Hospitalier Universitaire (CHU) de Montpellier, Montpellier Cedex 5, France

T. Asselah
Department of Hepatology, Hopital Beaujon, AP-HP, Paris University and INSERM UMR 1149, Clichy, France

P. Lampertico
Foundation IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Policlinico-Division of Gastroenterology and Hepatology-CRC 'AM and A Migliavacca' Centre for Liver Disease, Milan, Italy

P. Lampertico
University of Milan, Milan, Italy

A. Aghemo (✉)
Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital IRCCS, Via A. Manzoni 56, 20089 Rozzano, Milan, Italy
e-mail: Alessio.aghemo@hunimed.eu

C. Roncero
Institute of Biomedicine and School of Medicine, University of Salamanca, Salamanca, Spain

F. Negro
Division of Clinical Pathology, University Hospital, Geneva, Switzerland

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regu-

lation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.